Artificial Intelligence (AI)-Enhanced Remote Patient Intravenous (IV) Monitoring Global Market Report 2025

The artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market size has grown rapidly in recent years. It will grow from $1.39 billion in 2024 to $1.69 billion in 2025 at a compound annual growth rate (CAGR) of 21.8%. The growth during the historic period can be attributed to the increasing prevalence of chronic diseases requiring long-term infusions, the shift from inpatient to outpatient infusion centers, growth in oncology and immunology biologic therapies, post-pandemic adoption of remote care models, and nurse staffing shortages creating a greater need for remote oversight.

The artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market size is expected to see rapid growth in the next few years. It will grow to $3.67 billion in 2029 at a compound annual growth rate (CAGR) of 21.4%. The growth during the forecast period can be attributed to the expansion of hospital-at-home programs and coverage, continued growth of specialty infusion drugs for oncology and autoimmune diseases, ongoing nursing workforce shortages and burnout, value-based care incentives linked to safety and outcomes, and payer policies encouraging appropriate home-based infusions. Key trends in the forecast period include computer vision-based detection of extravasation and infiltration, multispectral optical sensing to monitor tissue changes at the cannula site, edge AI on sensor patches for on-device analytics, predictive analytics models for occlusions, air-in-line, and flow anomalies, and electronic health record interoperability using Fast Healthcare Interoperability Resources (FHIR) application programming interfaces.

The expansion of telehealth services is expected to drive the growth of the artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market. Telehealth services utilize digital communication technologies to provide remote medical consultations, monitoring, and treatment. Regulatory changes and reimbursement policies introduced during the COVID-19 pandemic have increased accessibility and financial viability for both providers and patients. AI-enhanced remote patient IV monitoring supports telehealth by enabling real-time tracking of IV therapy, detecting complications automatically, providing actionable insights to healthcare providers, and integrating with virtual care platforms to ensure timely interventions, improved patient safety, and efficient management of home-based and outpatient treatments. For example, in April 2023, FAIR Health Inc., a US-based non-profit organization, reported that national telehealth use increased by 7.3%, rising from 5.5% of medical claim lines in December 2022 to 5.9% in January 2023. The expansion of telehealth services is therefore driving growth in the AI-enhanced remote patient IV monitoring market.

The proliferation of wearable health technologies is expected to propel market growth. Wearable devices such as smartwatches and fitness trackers monitor health metrics in real time. Increasing health awareness and the demand for real-time health insights are driving the adoption of these technologies. Wearable health technologies support remote patient IV monitoring by continuously collecting physiological data, enabling the detection of anomalies, optimization of IV treatments, and timely, personalized interventions without constant in-person supervision. For instance, in April 2025, the UK Parliament's House of Commons Library reported that between 2023 and 2024, the NIHR and UKRI invested approximately USD 15 million (£11.5 million) in 10 research projects developing wearable technologies to support independence for people living with frailty or long-term physical disabilities. The proliferation of wearable health technologies is thus contributing to the growth of the AI-enhanced remote patient IV monitoring market.

Increasing healthcare expenditure is expected to support the growth of the AI-enhanced remote patient IV monitoring market. Rising financial resources in healthcare reflect growing demand for advanced medical technologies and services aimed at improving patient outcomes, enhancing treatment efficiency, and supporting AI-enabled remote monitoring. Higher healthcare expenditure facilitates investment in advanced technologies, digital infrastructure, and staff training to ensure more efficient and accurate patient care. For example, in June 2025, the Centers for Medicare & Medicaid Services reported that in 2023, national health expenditures increased by 7.5% to reach $4.9 trillion, averaging $14,570 per person and representing 17.6% of GDP. Medicare spending rose by 8.1% to $1.02 trillion, accounting for 21% of total national health expenditures. Increasing healthcare expenditure is therefore driving the growth of the AI-enhanced remote patient IV monitoring market.

Major players in the artificial intelligence (ai)-enhanced remote patient intravenous (iv) monitoring market are Medtronic plc, Siemens Healthineers AG, GE HealthCare Technologies Inc., Koninklijke Philips N.V., Baxter International Inc., B. Braun Melsungen AG, Terumo Corporation, Nipro Corporation, Epic Systems Corporation, ICU Medical Inc., InfuSystem Holdings Inc., AlayaCare Inc., Huma Therapeutics Ltd., Health Recovery Solutions Inc., Arcomed AG, VitalConnect Inc., Cloud DX Inc., Empatica S.r.l., AccuHealth Inc., Serum Tracker Inc.

North America was the largest region in the artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market research report is one of a series of new reports that provides artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market statistics, including artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring industry global market size, regional shares, competitors with the artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market share, artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market segments, market trends, and opportunities, and any further data you may need to thrive in the artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring industry. This artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring is a system that employs AI algorithms to continuously track and analyze IV therapy data in real time. It can identify irregularities, predict potential complications, and optimize fluid or medication delivery based on patient-specific patterns. The technology combines sensors, data analytics, and automated alerts to enhance safety and efficiency in IV treatment management.

The primary components of AI-enhanced remote patient intravenous (IV) monitoring include hardware, software, and services. Hardware comprises physical equipment and devices that collect, process, and support system operations, such as infusion pumps and wearable patient monitors. These systems can be deployed on-premises or via cloud platforms. They are applied in various settings, including hospitals, clinics, homecare, ambulatory surgical centers, and others, and are used by diverse end-users such as healthcare providers and patients.

The countries covered in the artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market consists of revenues earned by entities by providing services such as continuous IV flow monitoring, AI-powered predictive analytics, remote patient monitoring, automated alerts and notifications, data management and reporting, telehealth integration, device management and support, and medication management support. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI)-enhanced remote patient intravenous (IV) monitoring market also includes sales of flow meters, pressure transducers, wireless control interfaces for infusion pumps, cloud-integrated drug infusion systems, and AI-enhanced remote monitoring platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.